Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Natural human erythropoietin analogue

A technology for erythropoietin and analogs, applied in the field of erythropoietin analogs or their variants, recombinant plasmids and host cells, and can solve problems such as decreased in vitro activity

Active Publication Date: 2013-05-22
SHENYANG SUNSHINE PHARMA
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, another study showed that if the asparagine or serine residues as glycosylation sites were mutated to remove N-linked or O-linked oligosaccharide chains individually or together, it would make the mammalian cells The in vitro activity of the mutant protein produced in the drug decreased sharply (Dube et al., J.Biol.Chem.263:17516, 1988)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Natural human erythropoietin analogue
  • Natural human erythropoietin analogue
  • Natural human erythropoietin analogue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1: Construction of Human Erythropoietin Analog DNA Fragment

[0058] There are three natural N-glycosylation sites in the amino acid sequence of human erythropoietin, which are respectively located at positions 24, 38 and 83. The positions that promote erythropoietin to produce additional glycosylation sites can be 2, 3, 4, 28, 30, 88 (see figure 1 ).

[0059] Combination between mutation groups for the above positions, such as constructing [Asn 2 Gly 3 Thr 4 ], [Asn 28 Thr 30 ], [Asn 88 Gly 89 Ser 90 ], adding N-glycosylation sites at positions 2, 28, and 88, and enhancing the glycosylation at this position by changing the amino acid sequence of the middle position or the position before the glycosylation site.

[0060] For primers additionally adding N-glycosylation site mutations, refer to SEQ ID NOS: 2-85. Using these primers, the erythropoietin analogue DNA fragment after mutation can be obtained by performing polymerase chain reaction (PCR) with ...

Embodiment 2

[0085] Example 2: Asn 2 Gly 3 Thr 4 Preparation of EPO

[0086] A. Construction, screening and cultivation of engineered cells

[0087] The plasmid pEC4-N1 constructed according to the method of Example 1 was transfected into CHO cells. The host cells were purchased from the American Type Culture Collection (ATCC) and were dihydrofolate reductase-deficient Chinese hamster ovary cells (CHO dhfr-). Culture the cells in a 100mm culture dish, and when the cells grow to 60-95% full, rinse the cells with serum-free medium, add a transfection mixture composed of 5ml serum-free medium, 10μg pEC4-N1, and 60μg lipofectamine , cultured at 37°C for 4 hours, aspirated the medium, added MEM medium containing 5% fetal bovine serum, and cultured overnight at 37°C. Then add MTX to the culture medium and continue to culture for 10-14 days until resistant clones appear. The cultured cells of the resistant clone were digested with trypsin, the MTX concentration was increased, and the resist...

Embodiment 3

[0096] Example 3: Asn 3 Phe 4 Ser 5 Preparation of EPO

[0097] A. Construction, screening and cultivation of engineered cells

[0098] The plasmid pEC4-N2 constructed according to the method of Example 1 was transfected into CHO cells. The host cells were purchased from the American Type Culture Collection (ATCC) and were dihydrofolate reductase-deficient Chinese hamster ovary cells (CHO dhfr-). Culture the cells in a 100mm culture dish, and when the cells grow to 60-95% full, rinse the cells with serum-free medium, add a transfection mixture composed of 5ml serum-free medium, 10μg pEC4-N2, and 60μg lipoFectamin , cultured at 37°C for 4 hours, aspirated the medium, added MEM medium containing 5% fetal bovine serum, and cultured overnight at 37°C. Then add MTX to the culture medium and continue to culture for 10-14 days until resistant clones appear. The cultured cells of the resistant clone were digested with trypsin, the MTX concentration was increased, and the resista...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an erythropoietin analogue containing at least one extra glycosylation site or a variant of the erythropoietin analogue. The invention also relates to a DNA (Deoxyribonucleic Acid) sequence for encoding the erythropoietin analogue or the variant thereof as well as a recombinant plasmid and a host cell which are supplied for the analogue or the variant thereof to express.

Description

[0001] This application is a divisional application of an invention patent application with an application date of July 2, 2007, an application number of 200710127362.7, and a title of "a new erythropoietin analogue". technical field [0002] The invention belongs to the technical field of genetic engineering, and in particular relates to an erythropoietin analog or a variant thereof with at least one additional glycosylation site. The present invention also relates to the DNA sequence encoding the erythropoietin analog or its variant, as well as the recombinant plasmid and host cell expressing the analog or its variant. Background technique [0003] Erythropoietin (EPO) is the first hematopoietic growth factor discovered and used clinically. As early as 1906, Carnot et al. found that after blood loss in rabbits, a substance that could act on the hematopoietic system to accelerate red blood cell production would be produced in the peripheral blood, thus proposing that there ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/505C12N15/12C12N15/63C12N5/10C12P21/02A61K38/18A61P7/06
Inventor 娄竞耿建玲张杰侯绪凤赵会林陆军苏冬梅胡金东
Owner SHENYANG SUNSHINE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com